Adaptive Biotechnologies Corp
ADPT18.610USD
+2.290+14.03%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
2.84BMarket Cap
LossP/E TTM
More Details of Adaptive Biotechnologies Corp Company
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).
Adaptive Biotechnologies Corp Info
Ticker SymbolADPT
Company nameAdaptive Biotechnologies Corp
IPO dateJun 27, 2019
CEOMr. Chad M. Robins
Number of employees619
Security typeOrdinary Share
Fiscal year-endJun 27
Address1165 Eastlake Ave E
CitySEATTLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code98109
Phone12066590067
Websitehttps://www.adaptivebiotech.com
Ticker SymbolADPT
IPO dateJun 27, 2019
CEOMr. Chad M. Robins
Company Executives of Adaptive Biotechnologies Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.01M
-4.25%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Director
Independent Director
54.30K
+41.54%
Mr. Kyle Piskel
Mr. Kyle Piskel
Chief Financial Officer
Chief Financial Officer
47.15K
-0.50%
Ms. Karina Calzadilla
Ms. Karina Calzadilla
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Julie Rubinstein
Ms. Julie Rubinstein
President, Chief Operating Officer
President, Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.01M
-4.25%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
MRD revenue
49.94M
84.81%
Immune meidicine revenue
8.94M
15.19%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
MRD revenue
49.94M
84.81%
Immune meidicine revenue
8.94M
15.19%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Viking Global Investors LP
19.65%
The Vanguard Group, Inc.
7.37%
BlackRock Institutional Trust Company, N.A.
7.15%
Columbia Threadneedle Investments (US)
3.79%
Amova Asset Management Co., Ltd.
2.39%
Other
59.66%
Shareholders
Shareholders
Proportion
Viking Global Investors LP
19.65%
The Vanguard Group, Inc.
7.37%
BlackRock Institutional Trust Company, N.A.
7.15%
Columbia Threadneedle Investments (US)
3.79%
Amova Asset Management Co., Ltd.
2.39%
Other
59.66%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
49.25%
Investment Advisor
37.12%
Hedge Fund
7.29%
Individual Investor
2.58%
Research Firm
1.98%
Venture Capital
0.61%
Bank and Trust
0.29%
Pension Fund
0.28%
Insurance Company
0.16%
Other
0.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
495
149.78M
98.11%
-10.12M
2025Q2
498
148.68M
97.64%
-4.69M
2025Q1
498
156.30M
102.90%
-1.29M
2024Q4
481
143.31M
96.47%
-18.10M
2024Q3
478
143.38M
97.20%
-27.99M
2024Q2
486
149.83M
101.63%
-16.40M
2024Q1
506
146.67M
99.58%
-10.66M
2023Q4
529
145.23M
100.12%
-16.05M
2023Q3
531
142.64M
98.54%
-11.65M
2023Q2
545
137.84M
95.31%
-15.76M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Viking Global Investors LP
29.99M
19.7%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
11.26M
7.39%
+140.86K
+1.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.07M
7.27%
+1.28M
+13.03%
Jun 30, 2025
Columbia Threadneedle Investments (US)
2.36M
1.55%
-4.13M
-63.68%
Jun 30, 2025
Amova Asset Management Co., Ltd.
4.30M
2.82%
-1.79M
-29.35%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.22M
2.11%
+434.35K
+15.62%
Jun 30, 2025
ARK Investment Management LLC
4.02M
2.64%
-382.18K
-8.69%
Jun 30, 2025
Aristotle Atlantic Partners, LLC
2.88M
1.89%
-61.90K
-2.10%
Jun 30, 2025
State Street Investment Management (US)
3.03M
1.99%
+337.63K
+12.55%
Jun 30, 2025
Driehaus Capital Management, LLC
2.42M
1.59%
+271.25K
+12.60%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ARK Genomic Revolution ETF
4.15%
Franklin Genomic Advancements ETF
3.84%
ROBO Global Healthcare Technology & Innovation ETF
2.04%
Invesco Dorsey Wright Industrials Momentum ETF
1.62%
First Trust Nasdaq Lux Digi Health Solutions ETF
1.02%
Even Herd Long Short ETF
0.85%
First Trust Small Cap Growth AlphaDEX Fund
0.71%
Invesco Dorsey Wright SmallCap Momentum ETF
0.57%
Invesco NASDAQ Future Gen 200 ETF
0.55%
iShares Micro-Cap ETF
0.42%
View more
ARK Genomic Revolution ETF
Proportion4.15%
Franklin Genomic Advancements ETF
Proportion3.84%
ROBO Global Healthcare Technology & Innovation ETF
Proportion2.04%
Invesco Dorsey Wright Industrials Momentum ETF
Proportion1.62%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion1.02%
Even Herd Long Short ETF
Proportion0.85%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.71%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.57%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.55%
iShares Micro-Cap ETF
Proportion0.42%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Adaptive Biotechnologies Corp?
The top five shareholders of Adaptive Biotechnologies Corp are:
Viking Global Investors LP holds 29.99M shares, accounting for 19.70% of the total shares.
The Vanguard Group, Inc. holds 11.26M shares, accounting for 7.39% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.07M shares, accounting for 7.27% of the total shares.
Columbia Threadneedle Investments (US) holds 2.36M shares, accounting for 1.55% of the total shares.
Amova Asset Management Co., Ltd. holds 4.30M shares, accounting for 2.82% of the total shares.
Viking Global Investors LP holds 29.99M shares, accounting for 19.70% of the total shares.
The Vanguard Group, Inc. holds 11.26M shares, accounting for 7.39% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.07M shares, accounting for 7.27% of the total shares.
Columbia Threadneedle Investments (US) holds 2.36M shares, accounting for 1.55% of the total shares.
Amova Asset Management Co., Ltd. holds 4.30M shares, accounting for 2.82% of the total shares.
What are the top three shareholder types of Adaptive Biotechnologies Corp?
The top three shareholder types of Adaptive Biotechnologies Corp are:
Viking Global Investors LP
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Viking Global Investors LP
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Adaptive Biotechnologies Corp (ADPT)?
As of 2025Q3, 495 institutions hold shares of Adaptive Biotechnologies Corp, with a combined market value of approximately 149.78M, accounting for 98.11% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.47%.
What is the biggest source of revenue for Adaptive Biotechnologies Corp?
In FY2025Q2, the MRD revenue business generated the highest revenue for Adaptive Biotechnologies Corp, amounting to 49.94M and accounting for 84.81% of total revenue.
